Abcuro, Inc Email Formats

Biotechnology Research • United States • 51-100 Employees

Abcuro, Inc Email Formats

Abcuro, Inc uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@abcuro.com), used 85.4% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@abcuro.com	85.4%
{first name}.{last name}	john.doe@abcuro.com	14.6%

Key Contacts at Abcuro, Inc

Claus Sundgreen

Consultant Medical Director

Hugo Lemessurier

Director

Alex Martin

Chief Executive Officer

Raquel Orozco

Director, Head Of Cmc Process Development

Kristin Lurk

Senior Director, Program Management

Christopher Duymich

Director, Cmc Project Management

Samantha Lewis

Associate Director, Cmc Supply Chain And Logistics

Chidi Obi

Director Analytical Development

Jeff Geary

Director, Human Resources

Andrew Marth

Director Of Quality Control

Company overview

Headquarters	United States
Phone number	+16177149759
Website	abcuro.com
NAICS	541714
SIC	283
Employees	51-100
Socials

About Abcuro, Inc

Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated bycytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies. IBM is a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.